News
EQS-News: MEDICLIN on track: business development in line with expectations
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights:
-
Revenue grew 22% year-over-year
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Dexcom Appoints Euan Ashley to Board of Directors
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025.
Dr. Ashley is a
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1)
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery
Humana Partners to Expand Mental Health Education for Louisville’s Next Generation
Following World Mental Health Day, the Humana Foundation – the philanthropic arm of Humana Inc. for the past 44 years – along with Jewish Heritage Fund and the University of Louisville’s Christina
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming
Sonova expands AI leadership with innovations debuting at EUHA 2025